Amicus Therapeutics Inc (LTS:0HF9)
$ 9.978 -0.0808 (-0.8%) Market Cap: 2.98 Bil Enterprise Value: 3.18 Bil PE Ratio: 0 PB Ratio: 16.66 GF Score: 81/100

Amicus Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 12, 2019 / 03:00PM GMT
Release Date Price: $11.81
Maryana Ilya Breitman
Goldman Sachs Group Inc., Research Division - Research Analyst

Good morning. My name is Maryana Breitman. I am a biotech analyst at Goldman Sachs. And firstly, I will read the disclaimer. We're required to make certain disclosures in public appearances about Goldman Sachs' relationships with companies that we discuss. The disclosures relate to [national] banking relationships, compensation received of 1% or more ownership. We're prepared to read out our disclosures for any issue or upon request. However, these disclosures are available in our most recent reports available to you as required on our firm's portal. Disclosures and updates to those disclosures are also available by ticker on the firm's public website. Also the news stated by non-Goldman Sachs personnel do not necessarily reflect those of Goldman Sachs.

It is my pleasure to welcome John Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics. Thanks, John.

John F. Crowley
Amicus Therapeutics, Inc. - Chairman & CEO

Maryana, good morning.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot